Sarepta Therapeutics Net Income Applicable To Common Shares Over Time
| SRPT Stock | USD 126.70 2.30 1.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sarepta Therapeutics Performance and Sarepta Therapeutics Correlation. Sarepta |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.54 | Revenue Per Share 16.921 | Quarterly Revenue Growth 0.408 | Return On Assets 0.0151 | Return On Equity 0.1227 |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Sarepta Therapeutics and related stocks such as Reata Pharmaceuticals, Mirati Ther, and Krystal Biotech Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KRYS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (7.9 M) | (10.9 M) | (19.1 M) | (32.2 M) | (69.6 M) | (140 M) | (126 M) | (119.7 M) |
| PTCT | 30.9 M | 30.9 M | (51.6 M) | (51.6 M) | (93.8 M) | (170.4 M) | (142.1 M) | (79 M) | (128.1 M) | (251.6 M) | (438.2 M) | (523.9 M) | (559 M) | (503.1 M) | (478 M) |
| IOVA | (25.7 M) | (25.7 M) | (3.3 M) | (33.8 M) | (12 M) | (27.7 M) | (102.3 M) | (92.1 M) | (123.6 M) | (197.6 M) | (259.6 M) | (342.3 M) | (395.9 M) | (356.3 M) | (338.5 M) |
| MDGL | (47.4 M) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (83.9 M) | (202.2 M) | (241.8 M) | (295.4 M) | (265.8 M) | (252.5 M) |
| VKTX | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (23.4 M) | (14.7 M) | (20.6 M) | (22.1 M) | (25.8 M) | (39.5 M) | (55 M) | (68.9 M) | (62 M) | (58.9 M) |
| HEPA | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (22.2 M) | (17 M) | (14.9 M) | (13.1 M) | (17.9 M) | (12.2 M) | (20.4 M) | (32.7 M) | (45.3 M) | (40.8 M) | (38.8 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.6 M) | (29.4 M) | (50.2 M) | (60.3 M) | (54.3 M) | (57 M) |
| AKRO | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (82.2 M) | (43.8 M) | (79.2 M) | (100.8 M) | (112 M) | (100.8 M) | (105.9 M) |
Sarepta Therapeutics and related stocks such as Reata Pharmaceuticals, Mirati Ther, and Krystal Biotech Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Sarepta Therapeutics | SRPT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 126.7
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.